

## ST6GALNAC6

### Native Human CA 19-9, Immunogen Grade

<b>Catalog No.</b>	CNH023	<b>Quantity:</b>	25 KU
<b>Alternate Names:</b>	CA 19-9, Carbohydrate antigen 19-9, Cancer antigen 19-9, sialyl-Lewis <sup>A</sup>		
<b>Description:</b>	CA 19-9 is the sialylated form of Lewis Antigen <sup>A</sup> . It is elevated in many types of gastrointestinal cancer, but it has been discouraged from being used as a screening test as it may be elevated in people who have no cancer. It is useful to distinguish pancreatic cancer from other diseases of the gland. In people whose red blood cells lack the Lewis antigen A, about 10% of the Caucasian population, CA 19-9 is not present on any cells, even in people with large tumors.		
<b>UniProt ID</b>	Q969X2		
<b>Gene ID:</b>	30815		
<b>Source:</b>	Human liver carcinoma		
<b>Concentration:</b>	> 1,000 KU/ml by EIA		
<b>Formulation:</b>	0.1 M PBS, pH 7.4 with sucrose, 0.05% NaN <sub>3</sub>		
<b>Purification:</b>	Ion exchange chromatography		
<b>Applications:</b>	Immunogen, ELISA Control		
<b>Application Notes:</b>	May contain very low levels of other cancer antigens.		
<b>Storage &amp; Stability:</b>	Upon initial thaw, prepare working aliquots and store at -20°C to -80°C.		
<b>Certification:</b>	Serum from donors has been tested and found to be negative for HIV-1/HIV-2, Hepatitis B Core Antigen, Hepatitis B Surface Antigen, Hepatitis C Virus and Syphilis by current FDA approved methods. However, because no test method can offer complete assurance that HIV, HBsAg, HCV, Syphilis or other infectious agents are absent, this material should be handled at the Bio-safety Level 2 (BSL 2) as recommended for any potentially infectious human serum or blood specimen in the CDC/NIH manual "Biosafety in Microbiological and Biomedical Laboratories", 1999.		

**NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**

